Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Time-release stimulant effective for once-daily treatment of ADHD

05.08.2002


First amphetamine-based long-acting stimulant offers all-day symptom control in children


A research team led by a Massachusetts General Hospital investigator has found that a long-acting form of the stimulant medication Adderall is effective in controlling symptoms of attention-deficit/hyperactivity disorder (ADHD) in children when taken in a single morning dose. The standard form of Adderall, which is made up of several amphetamine-based drugs, is only effective for four hours. This new formulation joins other long-acting stimulants, such as extended-release methylphenidate (Ritalin), in giving patients with ADHD a greater choice of medication. The report appears in the August issue of Pediatrics.

"Long-acting stimulants are very beneficial for children with ADHD, who otherwise have to go to the nurse’s office during the school day to receive their medication. And timed-release dosage avoids having frequent peaks and valleys of medication levels, giving the patient a more stable therapeutic environment," says Joseph Biederman, MD, director of Pediatric Psychopharmacology at MGH and the study’s lead author. "This medication gives us another treatment opportunity for those who cannot tolerate other stimulant drugs."

More than 500 children aged 6 to 12 who met standard diagnostic criteria for ADHD enrolled in the study at 47 sites across the country. Participants were randomly divided into four groups, and after a one-week "washout" period in which all participants received a placebo medication, three of the four groups began taking a 10 mg daily dose of the timed-release medication. The fourth group continued on placebo. After a week of 10 mg dosage, two of the three medication groups switched to a 20 mg dosage. And after another week, one group advanced to a 30 mg daily dosage. The study was double-blinded, meaning that study participants, their parents and the treating physicians did not know what dosages participants were receiving.



Throughout the four-week study period, participants received weekly evaluations from their physicians, and both parents and teachers completed weekly evaluations of the children’s behavior at home and at school. In addition, the children received complete physical examinations, including standard laboratory tests, before and at the end of the study.

Based on the results of both the teachers’ and parents’ evalutions, which used standardized behavioral surveys, even the 10 mg dosages of the timed-release medication produced significant behavioral improvements versus placebo throughout the day and into the evening. The higher dosages produced greater improvement, with the 30 mg dosage producing the best evaluations from both teachers and parents. No major adverse side-effects were reported.

The researchers note that not only does the long-acting medication eliminate the need for in-school administration - which should reduce missed doses and avoid publicly identifying students as having ADHD - but also a steady medication effect throughout the day will avoid the emergence of symptoms when drug levels begin to drop. In addition, symptom control persists into the evening, allowing coverage of homework and other after-school activities.

"By making ADHD treatment easier, less cumbersome and more private, long-acting stimulants can help improve patient compliance, resulting in better symptom control and an improved overall outcome for patients," says Biederman, who is also a professor of psychiatry at Harvard Medical School.


Biederman’s co-authors are Frank Lopez, MD, Children?s Development Center, Maitland, Fla.; Samuel Boellner, MD, Clinical Study Centers, Little Rock, Ark.; and Mark Chandler, MD, North Carolina Neuropsychiatry, Chapel Hill, N.C. The study was supported by a grant from Shire Pharmaceuticals, the manufacturer of Adderall.

The Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $300 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, transplantation biology and photomedicine. In 1994, the MGH joined with Brigham and Women’s Hospital to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups and nonacute and home health services.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>